What's new? Log in Free sign up

Hookipa Pharma (HOOK) News and press releases

Company Profile

News

From Benzinga Pro

What 4 Analyst Ratings Have To Say About HOOKIPA Pharma

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on HOOKIPA Pharma, Raises Price Target to $2.25

News, Price Target, Analyst Ratings

Morgan Stanley analyst Vikram Purohit maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Equal-Weight and raises the price target from $2 to $2.25.

12 Health Care Stocks Moving In Thursday's Intraday Session

Gamida Cell Appoints Terry Coelho As CFO, Effective Immediately

News, Management

Industry veteran Coelho brings more than 35 years of experience at emerging growth and global companies to role; Shai Lankry to leave company June 2Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn

HC Wainwright & Co. Reiterates Buy on HOOKIPA Pharma, Maintains $8 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Arthur He reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and maintains $8 price target.

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.

Recap: HOOKIPA Pharma Q1 Earnings

HOOKIPA Pharma Q1 EPS $(0.27) Misses $(0.23) Estimate, Sales $3.18M Miss $4.39M Estimate

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 32.5 percent increase over losses of $(0.40) per share from

Earnings Outlook For HOOKIPA Pharma

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's Intraday Session

Stocks That Hit 52-Week Lows On Friday

During Friday's session, 149 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

On Friday, 93 stocks made new 52-week lows.

Truist Securities Maintains Buy on HOOKIPA Pharma, Lowers Price Target to $4

News, Price Target, Analyst Ratings

Truist Securities analyst Asthika Goonewardene maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and lowers the price target from $11 to $4.

Looking Into HOOKIPA Pharma's Return On Capital Employed

HC Wainwright & Co. Reiterates Buy on HOOKIPA Pharma, Maintains $8 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Arthur He reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and maintains $8 price target.

HOOKIPA Pharma Q4 EPS $(0.17) Beats $(0.21) Estimate, Sales $7.83M Beat $7.07M Estimate

HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 73.85 percent increase over losses of $(0.65) per share from

Earnings Scheduled For March 15, 2023

Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.

HOOKIPA Pharma's Earnings Outlook

Press releases

From Benzinga Pro

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

News, Financing, Press Releases

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

Health Care, Press Releases

HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients with recurrent/metastatic head and neck cancer HOOKIPA is preparing to start a pivotal trial of

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Earnings, Press Releases

HOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

Press Releases, General

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

News, Press Releases

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

News, Press Releases

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today

Thinking about buying stock in Hookipa Pharma, Ford Motor, JPMorgan, Spotify Technology, or Wynn Resorts?

Small Cap, Opinion, Press Releases

NEW YORK, May 1, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HOOK, F, JPM, SPOT, and WYNN.

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

News, Press Releases, General

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today

HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference

News, Press Releases

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, April 14, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, the "Company")), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,

HOOKIPA Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook

Earnings, Press Releases

Data from Phase 2 study of HB-200 in combination with pembrolizumab in head and neck cancers expected in 2Q 2023 Phase 1 HB-300 trial in metastatic castration-resistant prostate cancer open for enrollment KRAS

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

News, Management, Press Releases

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.